SIETES :: 92381 citas

Resultados de la búsqueda por RETRASO MENTAL REFINAR BÚSQUEDA

1.

Iacobucci G. MHRA bans valproate prescribing for women not in pregnancy prevention programme. BMJ 2018;361:k1823. [Ref.ID 102614]

2.

Hirschler B. UK bans Sanofi epilepsy drug without pregnancy prevention plan. Reuters Health News 2018:24 de abril. [Ref.ID 102553]

3.

Pennell PB. Antiepileptic drugs in pregnancy — Quick decisions with long-term consequences. JAMA Neurology 2018:1. [Ref.ID 102464]

4.

Elkjær LS, Bech BH, Sun Y, Laursen TM, Christensen J. Association between prenatal valproate exposure and performance on standardized language and mathematics tests in school-aged children. JAMA Neurology 2018:1. [Ref.ID 102463]

5.

Anónimo. Medicines related to valproate: risk of abnormal pregnancy outcomes. Drug Safety Update 2015;8:1. [Ref.ID 98832]

6.

Doan T, Ware R, McPherson L, van Dooren K, Bain C, Carrington S, Einfeld S, Tonge B, Lennox N. Psychotropic medication use in adolescents with intellectual disability living in the community. Pharmacoepidemiol Drug Saf 2014;23:69-76. [Ref.ID 97001]

7.

Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. N Engl J Med 2008;359:262-73. [Ref.ID 83539]

8.

Tyrer P, Oliver-Africano P, Murphy D, Crawford M, Harley D. Antipsychotics in individuals with intellectual disability. Lancet 2008;371:1502. [Ref.ID 82799]

9.

Gainotti S, Galeotti F, Izzicupo F, Petrini C, Raschetti R. Antipsychotics in individuals with intellectual disability. Lancet 2008;371:1501-2. [Ref.ID 82798]

10.

Turk J, Bramble D, Levitas A. Antipsychotics in individuals with intellectual disability. Lancet 2008;371:1501. [Ref.ID 82797]

11.

Trollor JN, Somerville ER, Somerville HM. Antipsychotics in individuals with intellectual disability. Lancet 2008;371:1501. [Ref.ID 82796]

12.

Tyrer P, Oliver-Africano P, Ahmed Z, Bouras N, Cooray S, Deb S, Murphy D, Hare M, Meade M, Reece B, Kramo K, Bhaumik S, Harley D, Regan A, Thomas D, Rao B, North B, Eliahoo J, Karatela S, Soni A, Crawford M. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet 2008;371:57-63. [Ref.ID 81861]

13.

Matson JL, Wilkins J. Antipsychotic drugs for aggression in intellectual disability. Lancet 2008;371:9-10. [Ref.ID 81854]

14.

Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, Whitley CB, Feillet F, Feigenbaum AS, Bebchuk JD, Christ-Schmidt H, Dorenbaum A, for the Sapropterin Research Group. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenulketonuria: a phase III randomised placebo-controlled study. Lancet 2007;370:504-10. [Ref.ID 80886]

15.

Pey AL, Martinez A. Tetrahydrobiopterin for patients with phenylketonuria. Lancet 2007;370:462-3. [Ref.ID 80880]

16.

Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. Lancet 2006;368:2167-78. [Ref.ID 78680]

17.

Anónimo. Rispéridone. Troubles du comportement chez les enfants avec retard mental ou autisme: pas de progrès. Prescrire 2006;26:6. [Ref.ID 75760]

18.

de Koning TJ, Klomp LWJ, van Oppen ACC, Beemer FA, Dorland L, van den Berg IET, Berger R. Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency. Lancet 2004;364:2221-2. [Ref.ID 72194]

19.

Pollitt R J, Sharrard MJ. Treating rare inborn errors of metabolism. Lancet 2004;364:2158-60. [Ref.ID 72183]

20.

Valent F, Little D'A, Bertollini R, Nemer L E, Barbone F, Tamburlini G. Burden of disease attributable to selected environmental factors and injury among children and adolescents in Europe. Lancet 2004;363:2032-9. [Ref.ID 70482]